Brief: Palvella Therapeutics Doses First Patients In Phase 2 Toiva Clinical Trial Of Qtorin
08/01/2025 14:00
Jan 8 (Reuters) - Palvella Therapeutics Inc PVLA.O :
* PALVELLA THERAPEUTICS ANNOUNCES FIRST PATIENTS DOSED IN
PHASE 2
TOIVA CLINICAL TRIAL OF QTORIN™ 3.9% RAPAMYCIN ANHYDROUS GEL
(QTORIN™ RAPAMYCIN) FOR THE TREATMENT OF CUTANEOUS VENOUS
MALFORMATIONS
Source text: urn:newsml:reuters.com:*:nGNXnl0NQ
Further company coverage: PVLA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Palvella Therapeutics
See all newsPalvella Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Palvella Therapeutics Q2 net loss widens on higher expenses
Brief: Palvella Therapeutics Announces New Data From The Phase 2 Toiva Trial Of Qtorin™ Rapamycin In Cutaneous Venous Malformations
Brief: Palvella Therapeutics Announces Uplisting To The Nasdaq Global Market
Palvella Therapeutics' Q1 net loss widens on higher costs